Liberski, 2004 - Google Patents

Prion protein as a target for therapeutic interventions

Liberski, 2004

View PDF
Document ID
3983065678176737835
Author
Liberski P
Publication year
Publication venue
Pure and applied chemistry

External Links

Snippet

Transmissible spongiform encephalopathies (TSEs), currently known as prion diseases, are neurodegenerative disorders of the central nervous system (CNS) caused by an elusive infectious agent called “prion”(proteinaceous infectious particle). These dis orders include …
Continue reading at www.degruyter.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines

Similar Documents

Publication Publication Date Title
Aguzzi et al. Toward therapy of human prion diseases
Moreno-Gonzalez et al. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission
Collinge Mammalian prions and their wider relevance in neurodegenerative diseases
L. Sim Prion disease: chemotherapeutic strategies
Tagliavini et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro
Cashman et al. Prion diseases—close to effective therapy?
Aguzzi et al. Protein aggregation diseases: pathogenicity and therapeutic perspectives
Das et al. Prions: beyond a single protein
Mallucci et al. Rational targeting for prion therapeutics
Morales et al. Prion-like features of misfolded Aβ and tau aggregates
Neff et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders
Socias et al. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases
Noble et al. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding
Forloni et al. Therapy in prion diseases
Forloni et al. Clinical trials of prion disease therapeutics
Loeffler Antibody-mediated clearance of brain amyloid-β: mechanisms of action, effects of natural and monoclonal anti-Aβ antibodies, and downstream effects
Kabir et al. Emerging promise of immunotherapy for Alzheimer’s disease: a new hope for the development of Alzheimer’s vaccine
Elmoualij et al. Decontamination of Prions by the Flowing Afterglow of a Reduced‐pressure N2 O2 Cold‐plasma
Brown Drug therapy in human and experimental transmissible spongiform encephalopathy
Zafar et al. Therapies for prion diseases
Deriziotis et al. Prions and the proteasome
Marandi et al. Prion diseases–current theories and potential therapies: a brief review
Liberski Prion protein as a target for therapeutic interventions
Heppner et al. Pathogenesis of prion diseases: possible implications of microglial cells
Gu et al. IVIG delays onset in a mouse model of Gerstmann-Sträussler-Scheinker disease